Novo Nordisk has struggled to adapt to very high demand and a market where celebrities are more influential than doctors.

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

If you suspect someone has been taking Ozempic, or Mounjaro, or Wegovy, or yet another fat jab, is it impolite to ask them?

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Several new weight loss drugs are undergoing trials in the UK. These drugs will work similarly to those already available but ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Moderna announced layoffs affecting 10% of its workforce amid government and competitive challenges to its vaccine business ...